HCV Market Intelligence Report 2023
CHAI releases the third issue of the HCV Market Intelligence Report on HCV diagnostics and drugs in LMICs, including for the first time preliminary insights into harm reduction commodities. More
The Commission update focuses on national progress among the 20 countries most heavily burdened with viral hepatitis (75% of the global burden). An effective response in these countries is crucial if global elimination targets are to be achieved. More
A study provides new evidence regarding the registration and reimbursement of HCV therapies, including restrictions on reimbursement, permitting multicountry analyses and highlighting areas for growth. More
A diverse coalition of policymakers, scientists and civil society representatives unite in creating more humane drug policy by prioritizing the well-being of all impacted by the multifaceted challenges of illegal drug markets. Endorse NOW! More
C-EHRN releases a report focusing on the availability of and access to interventions that constitute the HCV continuum of care specific for people who inject drugs in 35 European cities. More
The 2023 update summarises some of the key developments in harm reduction and drug policy since the launch of the 8th edition of the Global State of Harm Reduction report in November 2022. More